Story perspectives

RSV Vaccines Slash Hospitalizations: 58% Drop in Seniors

11/10/2025

44 6

Summary

Story summary

From 2023 to 2025, Arexvy and Abrysvo reduced RSV-related hospitalizations by 58% in adults aged 60+, with stronger protection for those 75 and older.
Effectiveness was lower among immunocompromised individuals and those with cardiovascular disease.
mRESVIA had insufficient uptake for analysis.
In pediatric cases, the maternal RSV vaccine and Nirsevimab reduced infant hospitalizations, with the maternal vaccine cutting risk by 68% in three months and Nirsevimab 83.2% effective.

1 of 1

Story summary

From 2023 to 2025, Arexvy and Abrysvo reduced RSV-related hospitalizations by 58% in adults aged 60+, with stronger protection for those 75 and older.
Effectiveness was lower among immunocompromised individuals and those with cardiovascular disease.
mRESVIA had insufficient uptake for analysis.
In pediatric cases, the maternal RSV vaccine and Nirsevimab reduced infant hospitalizations, with the maternal vaccine cutting risk by 68% in three months and Nirsevimab 83.2% effective.